CompletedNot Applicable

CD160 Expression in Corneal Vessels

France43 participantsStarted 2021-04-21

Plain-language summary

Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

inclusion criteria : * 18-year-old or more patients * enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France * considered able to give an informed written consent exclusion criteria : * none

What they're measuring

Micro-vascular densities

Timeframe: 1 year

Trial details

NCT IDNCT05009407

SponsorCHU de Reims

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-22

View on ClinicalTrials.gov More Corneal Graft Rejection trials